medigraphic.com
ISSN 0210-5187 (Electronic)

2018, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2018; 46 (3)

Apremilast in severe atopic dermatitis: our experience

Benavente VFC, Sánchez MJM, Zayas GAI, Mateu PA

Language: Spanish
References: 11
Page: 176-179
PDF size: 282.94 Kb.


ABSTRACT

Apremilast is an oral phosphodiesterase-4 (PDE4) inhibitor approved in moderate-severe psoriasis and psoriatic arthritis. It has been used in various pathologies: erythema multiforme refractory to other treatments, Behçet disease, alopecia areata, hidradenitis suppurativa, among others. Currently, its use in severe atopic dermatitis (AD) refractory to other treatments is in the phase of clinical trials. We present five cases of severe AD with a long evolution, in which apremilast was prescribed off-label. In all cases, induction and maintenance regimen of 30 mg c/12 hours was implemented.


REFERENCES

  1. Keating G. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017; 77 (4): 459-472.

  2. Chen T, Levitt J, Geller L. Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J. 2017; 23 (1).

  3. Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut OB, Mat C et al. Apremilast for Behçet’s syndrome: a phase 2, placebo-controlled study. N Engl J Med. 2015; 372 (16): 1510-1518.

  4. Liu L, King B. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. 2017; 77 (4): 773-774.

  5. Weber P, Seyed Jafari S, Yawalkar N, Hunger R. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J Am Acad Dermatol. 2017; 76 (6): 1189-1191.

  6. Farahnik B, Beroukhim K, Nakamura M, Abrouk M, Zhu TH, Singh R et al. Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report. Dermatol Online J. 2017; 23 (5).

  7. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012; 11 (3): 341-346.

  8. Samrao A, Berry T, Goreshi R, Simpson E. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012; 148 (8): 890-897.

  9. Saporito R, Cohen D. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 2016; 8 (2): 179-184.

  10. Abrouk M, Farahnik B, Zhu T, Nakamura M, Singh R, Lee K et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017; 77 (1): 177-180.

  11. https://clinicaltrials.gov/show/NCT02087943.




2020     |     www.medigraphic.com